Notice: This company has been marked as potentially delisted and may not be actively trading. CymaBay Therapeutics (CBAY) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period 3 Biotech Stocks With Revolutionary Pipelines to Buy TodayJuly 29, 2024 | stocknews.comVanguard Group Inc. Purchases 598,707 Shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY)Vanguard Group Inc. lifted its position in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) by 11.6% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 5,747,587 shares of the biopharmaceutical company's stock after acquiring an additional 598,7April 6, 2024 | marketbeat.comCymaBay Therapeutics (NASDAQ:CBAY) Earns Sell Rating from Analysts at StockNews.comStockNews.com initiated coverage on CymaBay Therapeutics in a research note on Wednesday. They issued a "sell" rating on the stock.April 3, 2024 | marketbeat.comAssenagon Asset Management S.A. Invests $17.63 Million in CymaBay Therapeutics, Inc. (NASDAQ:CBAY)Assenagon Asset Management S.A. purchased a new position in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 746,353 shares of the biopMarch 28, 2024 | marketbeat.comGilead reduces 2024 earnings guidance after completing CymaBay takeoverMarch 22, 2024 | za.investing.comGilead Sciences Completes Acquisition Of CymaBay TherapeuticsMarch 22, 2024 | markets.businessinsider.comGilead Sciences Announces Completion of Acquisition of CymaBayMarch 22, 2024 | businesswire.comTrading was temporarily halted for "CBAY" at 07:03 PM with a stated reason of "News pending."March 22, 2024 | marketbeat.comCymaBay Therapeutics, Inc. (NASDAQ:CBAY) Shares Sold by Deutsche Bank AGDeutsche Bank AG cut its holdings in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) by 44.8% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 456,106 shares of the biopharmaceutical company's stock afterMarch 22, 2024 | marketbeat.comCymaBay Therapeutics (NASDAQ:CBAY) Reaches New 52-Week High at $32.48CymaBay Therapeutics (NASDAQ:CBAY) Sets New 1-Year High at $32.48March 18, 2024 | marketbeat.comCBAY Jul 2024 34.000 callMarch 16, 2024 | finance.yahoo.comCBAY Apr 2024 31.000 putMarch 16, 2024 | finance.yahoo.comCBAY Oct 2024 33.000 callMarch 16, 2024 | finance.yahoo.comCBAY Oct 2024 29.000 putMarch 16, 2024 | finance.yahoo.comCymaBay Therapeutics, Inc. (NASDAQ:CBAY) Sees Significant Drop in Short InterestCymaBay Therapeutics, Inc. (NASDAQ:CBAY - Get Free Report) was the target of a significant drop in short interest during the month of February. As of February 29th, there was short interest totalling 5,850,000 shares, a drop of 30.1% from the February 14th total of 8,370,000 shares. Based on an average daily volume of 3,630,000 shares, the days-to-cover ratio is currently 1.6 days.March 14, 2024 | marketbeat.comInvesting in CymaBay Therapeutics (NASDAQ:CBAY) three years ago would have delivered you a 540% gainMarch 11, 2024 | finance.yahoo.comGlenmede Trust Co. NA Buys Shares of 37,894 CymaBay Therapeutics, Inc. (NASDAQ:CBAY)Glenmede Trust Co. NA bought a new stake in CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 37,894 shares of the biopharmaceutical company's stock, valued at appMarch 10, 2024 | marketbeat.comSeven Eight Capital LP Purchases Shares of 41,556 CymaBay Therapeutics, Inc. (NASDAQ:CBAY)Seven Eight Capital LP purchased a new stake in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 41,556 shares of the biopharmaceutiMarch 9, 2024 | marketbeat.comCymaBay Therapeutics, Inc. (NASDAQ:CBAY) Position Lessened by Adage Capital Partners GP L.L.C.Adage Capital Partners GP L.L.C. trimmed its position in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) by 6.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,125,000March 5, 2024 | marketbeat.comCymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary CholangitisMarch 4, 2024 | globenewswire.comCymaBay Therapeutics (NASDAQ:CBAY) Sets New 1-Year High at $32.35CymaBay Therapeutics (NASDAQ:CBAY) Sets New 52-Week High at $32.35March 1, 2024 | marketbeat.com610,770 Shares in CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Acquired by MPM Bioimpact LLCMPM Bioimpact LLC bought a new position in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 610,770 shares of the biopharmaceutical companMarch 1, 2024 | marketbeat.comHC Wainwright Equities Analysts Lower Earnings Estimates for CymaBay Therapeutics, Inc. (NASDAQ:CBAY)CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) - Investment analysts at HC Wainwright reduced their FY2028 earnings per share estimates for shares of CymaBay Therapeutics in a note issued to investors on Thursday, February 29th. HC Wainwright analyst E. Arce now anticipates that the biophMarch 1, 2024 | marketbeat.comMaintaining Hold on CymaBay Amid Gilead Acquisition Deal ClosureFebruary 29, 2024 | markets.businessinsider.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of CymaBay Therapeutics, Inc. (CBAY)February 29, 2024 | markets.businessinsider.comCymaBay Therapeutics (NASDAQ:CBAY) Rating Reiterated by HC WainwrightHC Wainwright reaffirmed a "neutral" rating and set a $32.50 price target on shares of CymaBay Therapeutics in a research note on Thursday.February 29, 2024 | marketbeat.comCymaBay Therapeutics 4Q Loss/Shr 35c >CBAYFebruary 28, 2024 | marketwatch.comCymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate UpdateFebruary 28, 2024 | globenewswire.comAlgert Global LLC Purchases New Shares in CymaBay Therapeutics, Inc. (NASDAQ:CBAY)Algert Global LLC purchased a new stake in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 92,886 shares of the biopharmaceutical companFebruary 28, 2024 | marketbeat.comMonashee Investment Management LLC Acquires New Shares in CymaBay Therapeutics, Inc. (NASDAQ:CBAY)Monashee Investment Management LLC acquired a new stake in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 75,000 shares of the biopharmFebruary 25, 2024 | marketbeat.comCymaBay Therapeutics (CBAY) Price Target Increased by 12.84% to 31.37February 24, 2024 | msn.comCymaBay Therapeutics, Inc. (NASDAQ:CBAY) Shares Purchased by Swiss National BankSwiss National Bank increased its stake in CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) by 14.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 181,500 shares of the biopharmaceutical company's stock after purFebruary 23, 2024 | marketbeat.comCymaBay Therapeutics, Inc. (NASDAQ:CBAY) Stake Lessened by Deutsche Bank AGDeutsche Bank AG cut its holdings in CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) by 44.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 456,106 shares of the biopharmaceutical company's stock after selling 369,851 shares during the peFebruary 22, 2024 | marketbeat.comThe New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary CholangitisFebruary 21, 2024 | finance.yahoo.comThe New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary CholangitisFebruary 21, 2024 | prnewswire.comLeerink Partners Downgrades CymaBay Therapeutics (CBAY)February 20, 2024 | msn.comCymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 20, 2024 | globenewswire.comClariVest Asset Management LLC Sells 63,600 Shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY)ClariVest Asset Management LLC lowered its stake in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) by 39.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 96,481 shares of the biopharmFebruary 20, 2024 | marketbeat.comSVB Leerink Reaffirms Market Perform Rating for CymaBay Therapeutics (NASDAQ:CBAY)SVB Leerink restated a "market perform" rating and issued a $32.50 target price on shares of CymaBay Therapeutics in a research note on Tuesday.February 20, 2024 | marketbeat.comCymaBay Therapeutics, Inc. (NASDAQ:CBAY) Shares Acquired by New York State Common Retirement FundNew York State Common Retirement Fund lifted its position in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) by 39.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 64,4February 18, 2024 | marketbeat.comCYMABAY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CymaBay Therapeutics, Inc. - CBAYFebruary 16, 2024 | businesswire.comFY2026 Earnings Forecast for CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Issued By HC WainwrightCymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) - Research analysts at HC Wainwright raised their FY2026 EPS estimates for CymaBay Therapeutics in a note issued to investors on Tuesday, February 13th. HC Wainwright analyst E. Arce now forecasts that the biopharmaceutical company will postFebruary 15, 2024 | marketbeat.comCBAY Jan 2026 37.000 callFebruary 15, 2024 | finance.yahoo.comCBAY Feb 2024 33.000 callFebruary 14, 2024 | finance.yahoo.comCBAY Jan 2025 8.000 putFebruary 14, 2024 | finance.yahoo.comAnalysts Offer Predictions for CymaBay Therapeutics, Inc.'s FY2028 Earnings (NASDAQ:CBAY)CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) - Equities researchers at HC Wainwright issued their FY2028 earnings per share (EPS) estimates for CymaBay Therapeutics in a note issued to investors on Tuesday, February 13th. HC Wainwright analyst E. Arce forecasts that the biopharmaceuticaFebruary 14, 2024 | marketbeat.comAnalysts see over 50% gains in these 2 mid-cap biotech stocks (CBAY)The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs.February 14, 2024 | marketbeat.comCymaBay Therapeutics (NASDAQ:CBAY) Earns Market Perform Rating from Lifesci CapitalLifesci Capital reissued a "market perform" rating on shares of CymaBay Therapeutics in a report on Wednesday.February 14, 2024 | marketbeat.comCymaBay Therapeutics (NASDAQ:CBAY) Sees Strong Trading VolumeCymaBay Therapeutics (NASDAQ:CBAY) Sees Unusually-High Trading VolumeFebruary 13, 2024 | marketbeat.comCymaBay's Seladelpar Is A Solid, But Pricey, Addition To Gilead's Liver FranchiseFebruary 13, 2024 | seekingalpha.com Get CymaBay Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CBAY and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners… Claim your FREE 2024 Gold Guide CBAY Media Mentions By Week CBAY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CBAY News Sentiment▼0.000.54▲Average Medical News Sentiment CBAY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CBAY Articles This Week▼03▲CBAY Articles Average Week Get CymaBay Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CBAY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Mirum Pharmaceuticals News Avid Bioservices News Rigel Pharmaceuticals News G1 Therapeutics News Viatris News Insmed News BioMarin Pharmaceutical News Dr. Reddy's Laboratories News Sarepta Therapeutics News Catalent News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CBAY) was last updated on 11/15/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredTop "Sleeping Giant" Crypto In The Market NowTop "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your fi...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredYou just voted for a financial crisisI’d like to share with you my #1 high-conviction stock to buy before Inauguration Day… and details on the asse...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CymaBay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CymaBay Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
